Payer Vs. Industry Views on Managed Entry Agreements.

Representatives from pharmaceutical companies (n=9) were interviewed, including senior personnel from pricing, market access, health economics and outcomes research and marketing. Payer proxies from the UK, France and Italy, such as health economists and payer advisors (n=10), were also interviewed. The different types of MEAs were presented to the respondents (Figure 1) at the outset of the discussion. The flow of the interview is summarised in Table 1.